The present invention relates generally to the fields of molecular biology and growth factor regulation. More specifically, the invention relates to therapies for the treatment of pathological conditions, such as cancer. Even more specifically, the invention relates to compositions comprising cobimetinib and vemurafenib and their use in the treatment of BRAF-V600 mutation-positive unresectable or metastatic melanoma.
